Ghost Tree Capital, LLC
- SEC CIK
- 0001595851
- Latest filing
- Nov 14, 2024
Holdings in Q4 2022
Holdings as of Dec 31, 2022, filed Feb 14, 2023. Long positions only; changes compare share counts with Q3 2022.
- Positions
- 35
- 0 vs. Q3 2022
- Portfolio value
- $234.2M
- −$10.7M (−4.4%) vs. Q3 2022
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| SYRESpyre Therapeutics, Inc. | COM | 800,000 | $360.0K | 0.2% | −200,000−20.0% | Reduced | History |
| DSGNDesign Therapeutics, Inc. | COM | 82,853 | $850.0K | 0.4% | −17,147−17.1% | Reduced | History |
| BPMCBlueprint Medicines Corp | COM | 20,000 | $876.0K | 0.4% | −45,000−69.2% | Reduced | History |
| XFORX4 Pharmaceuticals, Inc | COM | 1,000,000 | $993.0K | 0.4% | +1,000,000 | New | History |
| RXDXPrometheus Biosciences, Inc. | COM | 9,896 | $1.09M | 0.5% | +9,896 | New | History |
| WHWKWhitehawk Therapeutics, Inc. | COM | 90,000 | $1.16M | 0.5% | −110,000−55.0% | Reduced | History |
| TARSTarsus Pharmaceuticals, Inc. | COM | 80,000 | $1.17M | 0.5% | −40,000−33.3% | Reduced | History |
| Avidity Biosciences, Inc.05370A108 | COM | 100,000 | $2.22M | 0.9% | +100,000 | New | – |
| KZRKezar Life Sciences, Inc. | COM | 339,907 | $2.39M | 1.0% | −185,093−35.3% | Reduced | History |
| RAPTRAPT Therapeutics, Inc. | COM | 125,000 | $2.48M | 1.1% | +35,000+38.9% | Added | History |
| BCRXBiocryst Pharmaceuticals Inc | COM | 225,000 | $2.58M | 1.1% | −300,000−57.1% | Reduced | History |
| VKTXViking Therapeutics, Inc. | COM | 300,000 | $2.82M | 1.2% | +300,000 | New | History |
| SNDXSyndax Pharmaceuticals Inc | COM | 150,000 | $3.82M | 1.6% | −50,000−25.0% | Reduced | History |
| JBIOJade Biosciences, Inc. | COM | 135,000 | $3.96M | 1.7% | −15,000−10.0% | Reduced | History |
| PRVBProvention Bio, Inc. | COM | 400,000 | $4.23M | 1.8% | +400,000 | New | History |
| AKROAkero Therapeutics, Inc. | COM | 85,000 | $4.66M | 2.0% | +85,000 | New | History |
| VRDNViridian Therapeutics, Inc. | COM | 165,000 | $4.82M | 2.1% | −370,000−69.2% | Reduced | History |
| RVNCRevance Therapeutics, Inc. | COM | 300,000 | $5.54M | 2.4% | −90,000−23.1% | Reduced | History |
| MDGLMadrigal Pharmaceuticals, Inc. | COM | 20,000 | $5.80M | 2.5% | −5,000−20.0% | Reduced | History |
| ATXSAstria Therapeutics, Inc. | COM | 450,000 | $6.70M | 2.9% | −50,000−10.0% | Reduced | History |
| SRPTSarepta Therapeutics, Inc. | COM | 55,000 | $7.13M | 3.0% | −55,000−50.0% | Reduced | History |
| PCVXVaxcyte, Inc. | COM | 160,000 | $7.67M | 3.3% | −200,000−55.6% | Reduced | History |
| KRTXKaruna Therapeutics, Inc. | COM | 40,000 | $7.86M | 3.4% | +10,000+33.3% | Added | History |
| IOVAIovance Biotherapeutics, Inc. | COM | 1,300,000 | $8.31M | 3.5% | +1,300,000 | New | History |
| MRTXMirati Therapeutics, Inc. | COM | 200,000 | $9.06M | 3.9% | +25,000+14.3% | Added | History |
| COGTCogent Biosciences, Inc. | COM | 800,000 | $9.25M | 3.9% | +200,000+33.3% | Added | History |
| ISEEIVERIC bio, Inc. | COM | 450,000 | $9.63M | 4.1% | −13,700−3.0% | Reduced | History |
| SGENSeagen Inc. | COM | 85,000 | $10.9M | 4.7% | +85,000 | New | History |
| CTICCti Biopharma Corp | COM | 1,850,000 | $11.1M | 4.7% | −150,000−7.5% | Reduced | History |
| AMLXAmylyx Pharmaceuticals, Inc. | COM | 350,000 | $12.9M | 5.5% | −200,000−36.4% | Reduced | History |
| Invesco QQQ Trust Series I46090E103 | ETF | 50,000 | $13.3M | 5.7% | +50,000 | New | – |
| APLSApellis Pharmaceuticals, Inc. | COM | 300,000 | $15.5M | 6.6% | +25,000+9.1% | Added | History |
| ASNDAscendis Pharma A/S | SPONSORED ADR | 130,000 | $15.9M | 6.8% | +35,000+36.8% | Added | History |
| AXSMAxsome Therapeutics, Inc. | COM | 235,000 | $18.1M | 7.7% | −65,000−21.7% | Reduced | History |
| RETAReata Pharmaceuticals Inc | CL A | 500,000 | $19.0M | 8.1% | −225,000−31.0% | Reduced | History |
Sold out since Q3 2022 (9)
Positions held at the end of Q3 2022 that are gone from this filing.
| Security | Class | Shares in Q3 2022 | Value in Q3 2022 | % of portfolio in Q3 2022 | History |
|---|---|---|---|---|---|
| RLMDRelmada Therapeutics, Inc. | COM | 425,000 | $15.7M | 6.4% | History |
| ALTAltimmune, Inc. | COM NEW | 435,000 | $5.55M | 2.3% | History |
| FOLDAmicus Therapeutics, Inc. | COM | 500,000 | $5.22M | 2.1% | History |
| HZNPHorizon Therapeutics Public Ltd Co | SHS | 75,000 | $4.64M | 1.9% | History |
| ITCIIntra-Cellular Therapies, Inc. | COM | 60,000 | $2.79M | 1.1% | History |
| MLTXMoonLake Immunotherapeutics | CLASS A ORD | 300,000 | $2.33M | 1.0% | History |
| TCDATricida, Inc. | COM | 200,000 | $2.10M | 0.9% | History |
| RYTMRhythm Pharmaceuticals, Inc. | COM | 65,000 | $1.59M | 0.7% | History |
| BIIBBiogen Inc. | COM | 3,750 | $1.00M | 0.4% | History |